Targeting Nuclear Receptor Coactivators SRC-1/3 to Overcome AR-V7-mediated Antiandrogen Resistance
The NovoNGS CUT&amp;Tag 4.0 High-Sensitivity Kit (Novoprotein, N259-YH01) was employed to profile the genome-wide binding sites of AR-V7 in 22Rv1 cells under three conditions: (1) overexpression of AR-V7 alone; (2) co-overexpression of AR-V7 and SRC-1-HA; and (3) co-overexpression of AR-V7 and SRC-1-HA followed by a 24-hour treatment with EVG.